Go Pro
OTCMKTS:EMBI

Emerald Bioscience (EMBI) Stock Price, News & Analysis

Emerald Bioscience logo
$0.50 -0.04 (-7.30%)
As of 08/14/2026

About Emerald Bioscience Stock (OTCMKTS:EMBI)

Advanced

Key Stats

Today's Range
$0.47
$0.88
50-Day Range
$0.50
$0.80
52-Week Range
$0.02
$0.20
Volume
6.60 million shs
Average Volume
14.24 million shs
Market Capitalization
$134.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.

Receive EMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emerald Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EMBI Stock News Headlines

PIMCO Emerging Markets Bond Instl
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Sprint Bioscience AB SPRINT
Daré Bioscience, Inc. (DARE)
See More Headlines

EMBI Stock Analysis - Frequently Asked Questions

Emerald Bioscience's stock was trading at $0.6603 on March 14, 2026. Since then, EMBI shares have decreased by 24.0% and is now trading at $0.5015.

Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Emerald Bioscience investors own include Fulcrum Therapeutics (FULC), Gold Resource (GORO), Meta Platforms (META), Heatwurx (PCSA), Akero Therapeutics (AKRO) and

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:EMBI
CIK
N/A
Fax
N/A
Employees
4
Year Founded
2012

Profitability

EPS (Trailing Twelve Months)
($0.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.05 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-347.62%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
3.59
Quick Ratio
3.59

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
268,074,000
Free Float
N/A
Market Cap
$134.44 million
Optionable
Not Optionable
Beta
0.43

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (OTCMKTS:EMBI) was last updated on 8/19/2026 by MarketBeat.com Staff.
From Our Partners